Prostate Cancer Clinical Trials in Hackensack, New Jersey

6 studies are recruiting for prostate cancer in Hackensack, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

   The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Hackensack, New Jersey

   Locations

   346 in total

   Run by

   AstraZeneca

   See if you can join NCT06952803 on ClinicalTrials.gov

2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016), Hackensack, New Jersey

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

3. A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

   This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   John Theurer Cancer Center, Hackensack, New Jersey

   Locations

   2 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07543055 on ClinicalTrials.gov

4. Clinical Trial of Approaches to Prostate Cancer Surgery

   This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have simil…

   Stage

   Not phased

   Ages

   40 to 80

   Site

   Hackensack Meridian Health, Hackensack, New Jersey

   Locations

   9 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT05155501 on ClinicalTrials.gov

5. Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

   To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy

   Stage

   Not phased

   Ages

   18 and older

   Site

   John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

   Run by

   Hackensack Meridian Health

   See if you can join NCT07011342 on ClinicalTrials.gov

6. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hackensack University Medical Center, Hackensack, New Jersey

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov